NGEN (NervGen Pharma) Debt-to-Equity: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $1.78
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Debt-to-Equity?

NervGen Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. NervGen Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. NervGen Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NervGen Pharma's Debt-to-Equity or its related term are showing as below:

During the past 9 years, the highest Debt-to-Equity Ratio of NervGen Pharma was 0.06. The lowest was -0.10. And the median was 0.02.

NGEN's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

NervGen Pharma  (NAS:NGEN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NervGen Pharma Debt-to-Equity Related Terms

NervGen Pharma Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Debt-to-Equity Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.00 0.02 -0.10 0.04 0.00

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.06 -0.01 0.00 N/A

NGEN vs NKTX, UNCY, MDWD: Debt-to-Equity Comparison

For the Biotechnology subindustry, NervGen Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NervGen Pharma Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Debt-to-Equity falls into.


NGEN
22GF Score
NervGen Pharma Corp NGEN
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NervGen Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.006 + 0) / 2.52
=0.00

NervGen Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.78
Price